Kazia Therapeutics Expands Paxalisib Breast Cancer Trial to 36 Patients
KZIA has more than doubled off its 52-week low of $3.3.
Summary
Kazia Therapeutics is tripling patient enrollment in its Phase 1b trial for paxalisib in advanced breast cancer due to encouraging early data, aiming for more comprehensive efficacy assessment.
Key Events · Product Development and Regulatory · KZIA
-
Trial Expansion
Increased planned enrollment for the Phase 1b trial of paxalisib in advanced triple negative breast cancer from 12 to 36 patients.
-
Positive Early Data
Expansion is based on continued encouraging safety, tolerability, and clinical activity data observed to date.
-
Efficacy Assessment Focus
The expanded trial aims to provide a more meaningful assessment of objective response rate (ORR), progression-free survival (PFS), and translational biomarkers.
-
IP Protection Clarification
The company clarified that the withdrawal of ASCO 2026 abstracts was solely to protect intellectual property ahead of anticipated filings, not due to safety or clinical concerns.
Analysis · KZIA · Life Sciences
Kazia Therapeutics is expanding its Phase 1b trial for paxalisib in advanced triple negative breast cancer from 12 to 36 patients. This significant increase in enrollment is driven by encouraging safety, tolerability, and early clinical activity data, suggesting the drug's potential in a difficult-to-treat cancer. The expansion aims to gather more robust efficacy data, which is crucial for advancing the program. The company also clarified that recent abstract withdrawals from ASCO were for intellectual property protection, not safety concerns, addressing potential investor worries.
At the time of this filing, KZIA was trading at $13.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154.8M. The 52-week trading range was $3.30 to $17.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.